OpGen Announces Closing of Public Offering of Common Stock
March 29 2019 - 9:04AM
OpGen, Inc. (Nasdaq: OPGN) announced today the closing of its
previously announced underwritten public offering of 9 million
shares of its common stock at a public offering price of $0.60 per
share. All of the shares were sold by OpGen. The aggregate gross
proceeds to OpGen from the offering, before deducting the
underwriting discount and commissions and offering expenses, were
approximately $5.4 million.
Aegis Capital Corp. acted as the sole book-running
manager for the offering.
The shares were issued pursuant to a registration
statement previously filed with and subsequently declared effective
by the Securities and Exchange Commission (SEC). A final prospectus
was filed with the SEC on March 26, 2019. A copy of the final
prospectus relating to the offering, when available, may be
obtained by contacting Aegis Capital Corp., 810 7th Avenue, 18th
Floor, New York, NY 10019, (212) 813-1010 or by accessing the SEC's
website, www.sec.gov.
About OpGenOpGen,
Inc. is a precision medicine company harnessing the power of
molecular diagnostics and informatics to help combat infectious
disease. We are developing molecular information products and
services for global healthcare settings, helping to guide
clinicians with more rapid and actionable information about life
threatening infections, improve patient outcomes, and decrease the
spread of infections caused by multidrug-resistant microorganisms,
or MDROs.
Our molecular diagnostics and informatics products,
product candidates and services combine our Acuitas molecular
diagnostics and Acuitas Lighthouse informatics platform
for use with our proprietary, curated MDRO knowledgebase. We are
working to deliver our products and services, some in development,
to a global network of customers and partners. The Acuitas AMR
Gene Panel (RUO) is intended for Research Use Only and is not
for use in diagnostic procedures. The Acuitas Lighthouse
Software is not distributed commercially for antibiotic resistance
prediction and is not for use in diagnostic procedures. For more
information, please visit www.opgen.com.
OpGen, Acuitas, and Acuitas
Lighthouse are registered trademarks of OpGen, Inc.
OpGen Contact: Michael Farmer Vice
President, Marketing (240)
813-1284mfarmer@opgen.comInvestorRelations@opgen.com
Press Contact:Matthew
BretziusFischTank Marketing and PRmatt@fischtankpr.com
Investor Contacts: Joe GreenEdison
Groupjgreen@edisongroup.com
OpGen (NASDAQ:OPGN)
Historical Stock Chart
From Aug 2024 to Sep 2024
OpGen (NASDAQ:OPGN)
Historical Stock Chart
From Sep 2023 to Sep 2024